成都看腿部血管炎的医院(成都海绵状血管瘤哪个医院治得好) (今日更新中)

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

BEIJING, Feb. 18 (Xinhua) -- In the next five years, China will further expand the coverage of its basic medical insurance system and ease the cost of medical services, Health Minister Chen Zhu said Friday.Chen made the remarks while addressing a meeting for the reform of the health care system.The medical expenditure that shouldered by individuals had been cut to 38.2 percent of China's annual overall spending on medical services in 2009, down from 60 percent in 2001, thanks to increasing government funding support for the measure, said Chen.He said the country is striving to bring down the ratio to below 30 percent by the end of the country's 12th five-year plan period (2011-2015).China is steadily pushing towards the implementation of a basic medicine system which aims to ensure affordable access to essential drugs for patients, Chen said.In the areas already covered by basic medicine system, the average price of basic medicine has dropped by around 30 percent, Chen added.He said that the reform of government-run hospitals, which is key to ensure that the masses gain universal access to basic health care services, must be undertaken.In 2011, more measures will be made to restructure the distribution of public hospitals, reform government-run traditional Chinese medical institutions and support building and developing hospitals in county-level regions, Chen said.

MEXICO CITY, May 18 (Xinhua) -- The Mexican government signed an agreement with the non-governmental group TRAFFIC on Tuesday to exchange information about illegal seizures of flora and fauna species in Mexico.The agreement with the wildlife trade monitoring network also called for the Mexican government to provide information on the routes used to transport such organic materials.The agreement was signed on the sideline of the 16th meeting of the Trilateral Committee for Wildlife and Ecosystem Conservation Management in the city of Oaxaca, south Mexico. Representatives of Canada, the United States and Mexico also attended the meeting.Among the list of 20,000 animals, vegetation and insects that TRAFFIC considers to be threatened by illegal trafficking worldwide, 2,500 of the organisms have their origins in Mexico. This amounts to 12 percent of the species most subject to buying, selling and transporting in the black market and threatens the survival of various ecosystems.The Mexican species that are listed among the most threatened by illegal trafficking are the cactus, orchids, reptiles, maguey plants, ferns, amphibians and fish.

MOSCOW, April 22 (Xinhua) -- The Russian Space Forces has re-established contact with a military satellite, Geo-IK-2, which went missing in February, local media reported Friday.According to a spokesman from the Defense Ministry, Interfax news agency said the Space Forces had already received telemetric information from the satellite and collection and analysis of the data were currently underway.After studying the information, the Defense Ministry would make a decision regarding the further use of the satellite, the spokesman said.A Rokot light-class carrier rocket carrying with the Geo-IK-2 satellite blasted off Feb. 1 from Russia's Plesetsk launching site, but placed the satellite in an incorrect orbit. After the launch, the Defense Ministry announced it had lost contact with the Geo-IK-2 and later abandoned the satellite.The Russian Space Forces then grounded launches of all Rokot light-class carrier rockets until the completion of an investigation into the failed launch.

BEIJING, May 21 (Xinhua) -- China's State Food and Drug Administration (SFDA) issued a circular on Friday banning the use of Nimesulide, an anti-inflammatory drug, for children under the age of 12, considering potential side-effects such as liver and kidney damage.Nimesulide is a non-steroidal anti-inflammatory drug that first became available in Italy in 1985. It is now used in more than 50 countries and regions.The drug entered Chinese markets in 1997.According to the SFDA, while common adverse reactions to the drug include vomiting and stomache, domestic and overseas statistics indicate that more severe issues are related to the drug, such as blood coagulation disorders, decreased white blood cells and damage to liver and kidney.Previously, the SFDA only prevented the use of the drug among children one year old or younger.Also on Friday, the SFDA ordered the suspension of the production, sales and use of Duxil (almitrine and raubasine compound) due to its "unobvious" efficacy.According to the SFDA, clinical research found "little" evidence proving the drug effectively improves the cognitive ability for patients suffering vascular cognitive impairment.The drug was supposed to treat symptoms related to cognition and sensory nerve damage.The moves came after a two-month nationwide campaign was launched earlier this month to probe the quality of essential drugs and ensure drug safety.Official figures show that China's National Center for Adverse Drug Reaction Monitoring received 692,904 reports of adverse reactions in 2010, up 8.4 percent compared with those in 2009.Among the total, 109,991 cases involved new or severe adverse reactions, a year-on-year increase of 16.2 percent.

来源：资阳报